ERBB2 and ductal breast carcinoma in situ: It is specifically important that models also represent luminal A and luminal B subtypes as they account for about 50% and 20%, respectively, of all DCIS cases, whereas HER2 amplified accounts for 25% and the rare triple negative DCIS subtype only accounts for 5%, as they rapidly progress to invasive disease.14